Phase II Study of Cetuximab, Docetaxel and Cisplatin as First-line Treatment in Patients With Metastatic or Recurrent Head and Neck Squamous Cell Carcinomas - GORTEC2008-03 TPEx

Trial Profile

Phase II Study of Cetuximab, Docetaxel and Cisplatin as First-line Treatment in Patients With Metastatic or Recurrent Head and Neck Squamous Cell Carcinomas - GORTEC2008-03 TPEx

Completed
Phase of Trial: Phase II

Latest Information Update: 17 May 2017

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary)
  • Indications Head and neck cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms Tpex
  • Most Recent Events

    • 23 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 16 Jan 2014 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov
    • 14 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top